Duke Uses XRAD 225 CX to Test Radiosensitivity Hypothesis - Precision : Precision

Home / News + Events / News Story


Duke Uses XRAD 225 CX to Test Radiosensitivity Hypothesis

January 27, 2021

Image guided radiotherapy in a preclinical setting couldn’t be more useful than the treatment of brain tumors, where normal tissue damage can have severe and long lasting effects. Diffuse intrinsic pontine glioma (DIPG) kills more children than any other type of brain tumor. Despite clinical trials testing many chemotherapeutic agents, palliative radiotherapy remains the standard treatment. In this paper, tumor genotype dictates radiosensitization after ATM deletion in primary brainstem glioma models. While these tumors need more study, getting greater response rates with existing compounds is immediately translatable to the clinic. Here our friends at Duke, use XRAD 225 CX to test their hypothesis that greater radiosensitivity will lead to better response rates. Read it for yourself: https://lnkd.in/dw8baec

Next Post

Previous Post

Our goal is to be responsive and assist you in any way possible. Please feel free to contact us if you need more information or would like to speak with a Precision representative. Thank you for your interest in Precision.